Profile data is unavailable for this security.
About the company
Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.
- Revenue in SEK (TTM)1.21bn
- Net income in SEK-466.18m
- Incorporated2004
- Employees181.00
- LocationCalliditas Therapeutics ABD5, Kungsbron 1,STOCKHOLM 111 22SwedenSWE
- Phone+46 84113005
- Fax+46 86113303
- Websitehttps://www.calliditas.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nykode Therapeutics ASA | 138.34m | -382.11m | 4.33bn | 173.00 | -- | 2.33 | -- | 31.30 | -1.36 | -1.36 | 0.4861 | 5.76 | 0.0592 | -- | 10.01 | 807,899.70 | -16.36 | 5.65 | -19.00 | 6.38 | -- | -- | -276.22 | 18.13 | -- | -- | 0.0324 | -- | 79.99 | 282.17 | 17.75 | -- | 187.37 | -- |
| Deva Holding AS | 2.55bn | 771.63m | 4.87bn | 2.93k | 6.31 | 2.51 | 5.81 | 1.91 | 11.54 | 11.54 | 38.20 | 28.97 | 0.7464 | 1.49 | 6.52 | 2,686,365.00 | 22.55 | 21.33 | 43.27 | 33.37 | 56.78 | 53.72 | 30.21 | 32.51 | 0.9899 | -- | 0.4776 | 2.77 | 92.15 | 41.11 | 16.25 | 71.18 | 58.49 | -- |
| Guerbet SA | 9.14bn | 277.78m | 5.22bn | 2.92k | 19.74 | 1.18 | 5.39 | 0.5712 | 1.80 | 1.80 | 62.15 | 29.97 | 0.7997 | 0.5983 | 5.80 | 269,071.90 | 2.26 | 1.40 | 2.96 | 1.86 | 78.01 | 76.02 | 2.82 | 1.82 | 1.21 | 5.62 | 0.5035 | 57.82 | 4.30 | -0.0993 | 158.05 | -12.61 | 5.23 | -10.07 |
| Gen Ilac ve Saglik Urnlr Snyi ve Tcrt AS | 2.73bn | 151.97m | 5.75bn | 622.00 | 37.85 | 3.56 | 23.95 | 2.11 | 1.52 | 1.52 | 27.17 | 16.12 | 1.16 | 6.53 | 7.72 | 13,105,500.00 | 6.45 | 12.39 | 8.91 | 17.53 | 22.07 | 19.06 | 5.55 | 6.95 | 0.9854 | -- | 0.2095 | -- | -23.38 | 47.18 | -28.97 | 147.97 | -- | -- |
| Valneva SE | 1.79bn | -1.18bn | 5.82bn | 684.00 | -- | 3.88 | -- | 3.25 | -0.7343 | -0.7343 | 1.11 | 0.924 | 0.2843 | 2.54 | 4.69 | 224,726.60 | -18.76 | -15.39 | -31.44 | -25.06 | 34.37 | 35.94 | -65.99 | -34.95 | 1.37 | -3.57 | 0.6195 | -- | -57.46 | 6.34 | 29.21 | -- | 35.18 | -- |
| Calliditas Therapeutics AB | 1.21bn | -466.18m | 5.98bn | 181.00 | -- | 16.09 | -- | 4.96 | -8.69 | -8.69 | 22.49 | 6.24 | 0.6332 | 5.02 | 8.77 | 6,667,895.00 | -24.46 | -26.46 | -30.27 | -30.27 | 94.99 | -- | -38.63 | -76.59 | 3.08 | -4.44 | 0.7427 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
| Pharmanutra SpA | 1.17bn | 149.35m | 5.98bn | 105.00 | 39.79 | 9.38 | 34.15 | 5.13 | 1.33 | 1.33 | 10.41 | 5.66 | 0.9426 | 0.3648 | 4.90 | 954,304.80 | 12.07 | 18.39 | 16.12 | 24.80 | 97.56 | 96.36 | 12.81 | 17.77 | 1.83 | 57.61 | 0.3399 | 52.51 | 21.13 | 16.51 | -14.73 | 8.44 | 75.71 | 11.20 |
| Pharma Mar SA | 1.89bn | 23.58m | 6.07bn | 509.00 | 261.81 | 2.60 | 65.21 | 3.22 | 0.1086 | 0.1086 | 9.10 | 10.92 | 0.4583 | 0.2431 | 6.31 | 318,546.20 | 0.5726 | 18.52 | 0.7699 | 25.89 | 94.30 | 93.76 | 1.25 | 28.87 | 2.14 | -- | 0.17 | -- | -19.45 | 7.77 | -97.70 | -- | 46.37 | -- |
| Philogen SpA | 269.21m | -71.71m | 6.08bn | 160.00 | -- | 7.94 | -- | 22.57 | -0.1551 | -0.1551 | 0.5747 | 2.25 | 0.1887 | 6.65 | 7.95 | 144,562.50 | -5.03 | -7.32 | -5.56 | -8.36 | 40.04 | 32.04 | -26.64 | -58.66 | 6.84 | -- | 0.1414 | -- | -2.46 | 10.80 | -14.60 | -- | 51.78 | -- |
| Basilea Pharmaceutica AG Allschwil | 1.87bn | 124.24m | 6.32bn | 147.00 | 46.27 | -- | 44.08 | 3.37 | 0.8765 | 0.8765 | 13.15 | -0.8335 | 0.7999 | 1.06 | 5.16 | 1,072,340.00 | 5.30 | -1.86 | 7.69 | -2.99 | 83.00 | 83.45 | 6.63 | -2.99 | 2.64 | 2.02 | 1.10 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
| Boiron SA | 6.02bn | 554.22m | 6.94bn | 2.81k | 12.40 | 1.07 | 9.03 | 1.15 | 2.74 | 2.74 | 29.79 | 31.73 | 0.6792 | 1.36 | 6.57 | 184,705.80 | 6.14 | 5.08 | 7.56 | 6.39 | 73.88 | 75.12 | 9.04 | 7.40 | 2.54 | -- | 0.0225 | 48.87 | 17.36 | -2.86 | 56.44 | -10.60 | -19.01 | -7.22 |
| Pharming Group N.V. | 2.67bn | -114.77m | 7.07bn | 415.00 | -- | 2.97 | 120.78 | 2.65 | -0.0162 | -0.0162 | 0.3491 | 0.3048 | 0.5521 | 0.5089 | 6.65 | 552,605.30 | -2.37 | 5.26 | -2.81 | 6.63 | 89.72 | 89.41 | -4.30 | 9.26 | 3.33 | -4.00 | 0.4395 | -- | 19.30 | 9.01 | -177.14 | -- | -13.04 | -- |
| Gubra A/S | 319.91m | -69.48m | 7.50bn | 219.00 | -- | 9.98 | -- | 23.45 | -2.91 | -2.91 | 13.51 | 29.44 | -- | -- | -- | 936,095.90 | -- | -- | -- | -- | 56.06 | -- | -21.72 | -- | -- | -- | 0.1296 | -- | 2.82 | -- | -1,133.04 | -- | -- | -- |
| Surgical Science Sweden AB | 882.85m | 233.97m | 7.65bn | 260.00 | 32.67 | 1.76 | 26.41 | 8.66 | 4.59 | 4.59 | 17.32 | 85.16 | 0.1888 | 1.87 | 6.15 | 3,395,585.00 | 5.00 | 4.49 | 5.31 | 4.78 | 69.42 | 70.06 | 26.50 | 23.75 | 3.56 | -- | 0.00 | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
Data as of Apr 25 2024. Currency figures normalised to Calliditas Therapeutics AB's reporting currency: Swedish Krona SEK
30.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Dec 2022 | 5.77m | 9.69% |
| Fj�rde AP-fondenas of 31 Dec 2022 | 2.66m | 4.47% |
| Polar Capital LLPas of 29 Feb 2024 | 2.26m | 3.79% |
| Unionen (Investment Management)as of 31 Dec 2023 | 1.97m | 3.31% |
| Handelsbanken Fonder ABas of 31 Mar 2024 | 1.76m | 2.95% |
| E. �hman J :or Fonder ABas of 31 Dec 2023 | 1.33m | 2.23% |
| LSP Advisory BVas of 30 Jun 2023 | 845.89k | 1.42% |
| AXA Investment Managers UK Ltd.as of 29 Feb 2024 | 526.49k | 0.88% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 411.94k | 0.69% |
| SEB Investment Management ABas of 28 Mar 2024 | 373.40k | 0.63% |
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
